Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01371578 · ClinicalTrials.gov registry record · Phase 2
Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 163
- Enrollment target
NCT01371578 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 163 participants.
The verdict
NCT01371578, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 163 participants
- Enrollment target
Study Summary
This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection.
Interventions
- BIOLOGICAL peginterferon alfa-2a
- DRUG ribavirin tablet
- DRUG GS-5885 tablet
- DRUG GS-9451 tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 163 participants |
| Start Date | 2011-07 |
| Est. Completion | 2013-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01371578
The ClinicalTrials.gov registry entry for NCT01371578 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 163 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which peginterferon alfa-2a is the first listed.
NCT01371578 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01371578 about?
NCT01371578 is a clinical study titled "Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection". This is a Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy using Combinations of Oral Antivirals (GS-5885, tegobuvir, and/or GS-9451) with Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects with Chronic Genotype 1 Hepatitis C Virus (H...
What is the current status of trial NCT01371578?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 163 participants. The study started on 2011-07. Estimated completion is 2013-03.
What interventions are being tested in trial NCT01371578?
The interventions under investigation include: peginterferon alfa-2a (BIOLOGICAL), ribavirin tablet (DRUG), GS-5885 tablet (DRUG), GS-9451 tablet (DRUG).
Who is sponsoring clinical trial NCT01371578?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.